NASDAQ:ZSQR Coeptis Therapeutics (ZSQR) Stock Price, News & Analysis $16.73 0.00 (0.00%) As of 06/18/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Coeptis Therapeutics Stock (NASDAQ:ZSQR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coeptis Therapeutics alerts:Sign Up Key Stats Today's Range$15.28▼$16.8550-Day Range$8.16▼$16.7852-Week Range$6.80▼$21.41Volume1.11 million shsAverage Volume363,623 shsMarket Capitalization$860.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. Read More Coeptis Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreZSQR MarketRank™: Coeptis Therapeutics scored higher than 3% of companies evaluated by MarketBeat, and ranked 845th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingCoeptis Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCoeptis Therapeutics has received no research coverage in the past 90 days.Read more about Coeptis Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Coeptis Therapeutics is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coeptis Therapeutics is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoeptis Therapeutics has a P/B Ratio of 6.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.61% of the float of Coeptis Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoeptis Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coeptis Therapeutics has recently increased by 21.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoeptis Therapeutics does not currently pay a dividend.Dividend GrowthCoeptis Therapeutics does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coeptis Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.25% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions13.88% of the stock of Coeptis Therapeutics is held by institutions.Read more about Coeptis Therapeutics' insider trading history. Receive ZSQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coeptis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZSQR Stock News HeadlinesCoeptis Therapeutics (NASDAQ:ZSQR) Downgraded to "Sell" Rating by Wall Street ZenJune 13, 2026 | americanbankingnews.comZ Squared to Participate in Maxim Group's AI Data Center SummitJune 9, 2026 | prnewswire.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Z Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement to Support AI Infrastructure BuildoutJune 4, 2026 | prnewswire.comZ Squared, Inc. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® IndexesMay 27, 2026 | prnewswire.comVanderbilt Report: Z Squared Locks In Zero-Cash, Zero-Debt Path to 42 MW of AI-Ready PowerMay 26, 2026 | globenewswire.comZ Squared, Inc. Outlines Phase 1 Plan to Reach 100 MW of AI-Ready Infrastructure for Inference WorkloadsMay 19, 2026 | prnewswire.comZ Squared Appoints Jon Najarian, Pete Najarian, Marc LoPresti and Jay Zapata to Newly Formed Advisory BoardMay 4, 2026 | prnewswire.comSee More Headlines ZSQR Stock Analysis - Frequently Asked Questions How have ZSQR shares performed this year? Coeptis Therapeutics' stock was trading at $14.25 at the beginning of the year. Since then, ZSQR shares have increased by 17.4% and is now trading at $16.73. How were Coeptis Therapeutics' earnings last quarter? Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) issued its earnings results on Thursday, May, 14th. The company reported ($0.65) earnings per share for the quarter. The company had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative trailing twelve-month return on equity of 92.29% and a negative net margin of 810.04%. When did Coeptis Therapeutics' stock split? Shares of Coeptis Therapeutics reverse split on the morning of Tuesday, December 31st 2024.The 1-20 reverse split was announced on Friday, December 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Coeptis Therapeutics? Shares of ZSQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coeptis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coeptis Therapeutics investors own include Avino Silver & Gold Mines (ASM), PayPal (PYPL), Tesla (TSLA), Meta Platforms (META), 3M (MMM), PHX Minerals (PHX) and P3 Health Partners (PIII). Company Calendar Last Earnings5/14/2026Today6/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 9 days, ZSQR's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZSQR Previous SymbolNASDAQ:COEP CIK1759186 Webcoeptispharma.com Phone724-934-6467FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.92 million Net Margins-810.04% Pretax Margin-910.68% Return on Equity-92.29% Return on Assets-73.52% Debt Debt-to-Equity Ratio0.01 Current Ratio3.25 Quick Ratio3.25 Sales & Book Value Annual Sales$1.36 million Price / Sales632.66 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book6.36Miscellaneous Outstanding Shares51,430,000Free Float38,959,000Market Cap$860.42 million OptionableNot Optionable Beta-0.22 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ZSQR) was last updated on 6/20/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredForget the million-dollar nest eggNearly 2 in 3 Americans fear running out of money more than death - and chasing a $1.5 million nest egg isn't ...Investors Alley | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredRead this before you touch SPCXSPCX is live on Nasdaq - but a market expert who called AMD before it climbed as high as 7,100% says buying th...Altimetry | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredElon Now Pays 15X More Than Your BankElon Musk's new bank is offering 6% interest per year - that's 15 times the national average of 0.4% that most...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
